Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Freedberg

Showing results (271-280 of 325) with videos related to

Pageof 33
Sort By:
Plos One|October 27, 2010
Routine HIV screening in France: clinical impact and cost-effectivenessYazdan Yazdanpanah, Caroline E Sloan, Cécile Charlois-Ou, et al.
Annals of Internal Medicine|March 31, 2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infectionBenjamin P Linas, Devra M Barter, Jake R Morgan, et al.
Journal of the International AIDS Society|June 26, 2024
Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling studyAcadia M Thielking, Kieran P Fitzmaurice, Ronel Sewpaul, et al.
Plos Medicine|September 17, 2014
The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysisEmily P Hyle, Ilesh V Jani, Jonathan Lehe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2025
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the USPamela P Pei, Michelle Jones, Ruitian Hu, et al.
The Lancet. Global Health|May 29, 2025
Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysisElena Y Jin, Ali R Ahmed, Linda-Gail Bekker, et al.
AIDS (London, England)|April 15, 2015
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of ageAndrea L Ciaranello, Kathleen Doherty, Martina Penazzato, et al.
AIDS (London, England)|September 25, 2007
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapyKenneth A Freedberg, Nagalingeswaran Kumarasamy, Elena Losina, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 3, 2026
The Impact of Hearing Loss on Annual Incident Age-Associated Dementia Cases and Quality of Life in the USEthan D Borre, Julie N Deleger, Lauren K Dillard, et al.
BMC Health Services Research|December 6, 2025
Projecting lifetime HIV-related healthcare costs for youth with HIV in the United StatesMichelle L Jones, Sujata E Tewari, Joshua Espada, et al.
Pageof 33

Showing results (271-280 of 325) with videos related to

Sort By:
Pageof 33
Plos One|October 27, 2010
Routine HIV screening in France: clinical impact and cost-effectivenessYazdan Yazdanpanah, Caroline E Sloan, Cécile Charlois-Ou, et al.
Annals of Internal Medicine|March 31, 2015
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infectionBenjamin P Linas, Devra M Barter, Jake R Morgan, et al.
Journal of the International AIDS Society|June 26, 2024
Tobacco smoking, smoking cessation and life expectancy among people with HIV on antiretroviral therapy in South Africa: a simulation modelling studyAcadia M Thielking, Kieran P Fitzmaurice, Ronel Sewpaul, et al.
Plos Medicine|September 17, 2014
The clinical and economic impact of point-of-care CD4 testing in mozambique and other resource-limited settings: a cost-effectiveness analysisEmily P Hyle, Ilesh V Jani, Jonathan Lehe, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 4, 2025
Clinical consequences of delaying implementation of long-acting antiretroviral therapy for people with HIV and persistent viremia in the USPamela P Pei, Michelle Jones, Ruitian Hu, et al.
The Lancet. Global Health|May 29, 2025
Cost-effective pricing of long-acting injectable HIV pre-exposure prophylaxis for adolescent girls and young women in South Africa: a model-based analysisElena Y Jin, Ali R Ahmed, Linda-Gail Bekker, et al.
AIDS (London, England)|April 15, 2015
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of ageAndrea L Ciaranello, Kathleen Doherty, Martina Penazzato, et al.
AIDS (London, England)|September 25, 2007
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapyKenneth A Freedberg, Nagalingeswaran Kumarasamy, Elena Losina, et al.
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 3, 2026
The Impact of Hearing Loss on Annual Incident Age-Associated Dementia Cases and Quality of Life in the USEthan D Borre, Julie N Deleger, Lauren K Dillard, et al.
BMC Health Services Research|December 6, 2025
Projecting lifetime HIV-related healthcare costs for youth with HIV in the United StatesMichelle L Jones, Sujata E Tewari, Joshua Espada, et al.
Pageof 33